Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TEL AVIV, Israel, Sept. 14, 2017 -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference. The conference will be held September 25-27, 2017 at the InterContinental New York Barclay Hotel, New York City.
Presentation Details:
Date: Tuesday, September 26, 2017
Time: 9:45-10:15 AM Eastern Time
Location: Grand Ballroom 2; InterContinental New York Barclay Hotel
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC [email protected] (646) 597-6979 MEDIA CONTACT: Matt Middleman, M.D. LifeSci Public Relations [email protected] (646) 627-8384
